|
GB201418513D0
|
|
Compounds for the treatment of muscular dystrophy having improved bioavailability
|
|
GB201412010D0
|
|
Treatment of hypertransaminasemia
|
|
GB201404335D0
|
|
Selective glycosidase inhibitors and uses thereof
|
|
GB201404330D0
|
|
Selective glycosidase inhibitors and uses thereof
|
|
GB201404332D0
|
|
Selective glycosidase inhibitors and uses thereof
|
|
GB201403170D0
|
|
Preparation of antibacterial bisbenzimidazoles
|
|
GB201403177D0
|
|
Preparation and analysis of iminosugar acids
|
|
GB201304086D0
|
|
Selective glycosidase inhibitors and uses thereof
|
|
GB201304084D0
|
|
Selective glycosidase inhibitors and uses thereof
|
|
GB201304083D0
|
|
Selective glycosidase inhibitors and uses thereof
|
|
GB201303329D0
|
|
Preparation of antibacterial bisbenzimidazoles
|
|
GB201222768D0
|
|
Preparation and analysis of iminosugar acids
|
|
GB201215527D0
|
|
Compounds for the treatment of muscular dystrophy
|
|
GB201210390D0
|
|
Antibacterial enzyme inhibitors
|
|
GB201208178D0
|
|
Pharmaceutical composition for the treatment of duchenne muscular dystrophy
|
|
GB201205096D0
|
|
Use of iminosugars to enhance antibody-dependent cell-mediated cytotoxicity
|
|
GB201203984D0
|
|
Selective glycosidase inhinitors and uses thereof
|
|
GB201203988D0
|
|
Selective glycosidase inhibitors and uses thereof
|
|
GB201203987D0
|
|
Selective glycosidase inhibitors and uses thereof
|
|
GB201203617D0
|
|
Selective glycosidase inhibitors and uses thereof
|
